Total size of the offering in connection
with the initial public offering increased to a total amount of
€25.8m
Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY,
IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN
Genomic Vision (Paris:GV) (FR0011799907 – GV), a
molecular diagnostics company that specializes in the development
of diagnostic tests for genetic diseases and cancers using the DNA
molecular combing process, today announces that in connection with
its initial public offering on the regulated market of Euronext in
Paris, Société Générale, acting on behalf of the Joint Lead
Managers and Joint Bookrunners, partially exercised the
overallotment option allowing the issue of 185,000 new shares at
the offering price of €15 per share, corresponding to a total
amount of approximately €2.8m.
As a result, the total number of Genomic Vision’s shares offered
in connection with the initial public offering amounts to 1,718,332
new shares, thereby increasing the offering size to approximately
€25.8m.
In accordance, with the provisions of Article 631-10 of the
Règlement général of the French Autorité des marchés financiers,
Société Générale, acting as stabilizing agent, declares that:
- It has conducted stabilization
transactions on Genomic Vision’s shares (FR0011799907);
- The stabilization period started on
April 2nd, 2014;
- The stabilization period closed on
April 9th, 2014;
- Stabilization operations were conducted
within the following price range:
Date Low
price High price
02/04/2014 €15.00
€15.00
03/04/2014 €14.40
€15.00 04/04/2014
€14.46 €14.87
07/04/2014 €14.25
€14.75
08/04/2014 €14.00
€14.45 09/04/2014
€14.00 €14.49
Financial intermediaries
Bryan, Garnier & Co
Societe Generale
Joint Lead Managers and Joint Bookrunners
Sponsor Finance
Company Advisor
Availability of the prospectus – Copies of the
prospectus, which received a visa from the AMF on March 19th, 2014
under the number 14-087, composed of the document de base filed
with the AMF on March 3rd, 2014 under the number I. 14-005 and the
note d’opération (including a summary of the prospectus), may be
obtained free of charge at Genomic Vision’s headquarters, Green
Square - Bâtiment E, 80-84 rue des Meuniers, 92220 Bagneux, from
the internet websites of Genomic Vision (www.genomicvision.com) and
the AMF (www.amf-france.org).
Risk factors – Genomic Vision draws the public's
attention to chapter 4, “Risk factors”, of the document de base
registered with the AMF, and to chapter 2 “Risk factors related to
the Offering” of the note d’opération.
ABOUT GENOMIC VISION
A spinoff of the Institut Pasteur, Genomic Vision is a
molecular diagnostics company specialized in developing diagnostic
tests for genetic diseases and cancers. Using “molecular combing”,
an innovative technology that allows the direct visualization of
individual DNA molecules, Genomic Vision detects quantitative and
qualitative variations in the genome that are at the origin of
numerous serious pathologies. Having benefited from the financial
support of the Institut Pasteur, SGAM AI, Vesalius Biocapital and
Quest Diagnostics, the Company is developing a solid portfolio of
tests that notably target breast cancer and cancer of the colon.
Since 2013, the Company has marketed the CombHeliX FSHD test for
identifying a myopathy that is difficult to detect,
Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks
to a strategic alliance with Quest Diagnostics, the American leader
in diagnostic laboratory tests, and in France.
ABOUT MOLECULAR COMBING
DNA molecular combing technology considerably improves the
structural and functional analysis of DNA molecules. DNA fibers are
stretched out on glass slides, as if “combed”, and uniformly
aligned over the whole surface. It is then possible to identify
genetic anomalies by locating genes or specific sequences in a
patient’s genome using genetic markers, an approach developed by
Genomic Vision and patented under the name Genomic Morse Code. This
exploration of the entire genome at high resolution via a simple
analysis enables the direct visualization of genetic anomalies that
are undetectable by other technologies.
Pour en savoir plus: http://www.genomicvision.com
DISCLAIMER
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for GENOMIC VISION shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
In particular:
This press release does not constitute an offer to sell or any
solicitation to purchase or subscribe for securities in the United
States. The shares, or any other securities of GENOMIC VISION, may
not be offered or sold in the United States unless they are
registered under the U.S. Securities Act of 1933, as amended, or
exempt from registration. The shares of GENOMIC VISION have not
been and will not be registered under the U.S. Securities Act of
1933, as amended, and GENOMIC VISION does not intend to make any
public offer of its shares in the United States.
This press release is solely an advertisement and does not
constitute a prospectus within the meaning of Directive 2003/71/EC
of the European Parliament and the Council of November 4th, 2003,
as amended, in particular, by Directive 2010/73/EC of the European
Parliament and the Council of November 24th, 2010 and as
implemented in each member State of the European Economic Area (the
“Prospectus Directive”). With respect to the member States of the
European Economic Area which have transposed the Prospectus
Directive, no action has been undertaken or will be undertaken to
make an offer to the public of the securities referred to in this
press release requiring a publication by GENOMIC VISION of a
prospectus in any member State, other than France. As a result, the
shares of GENOMIC VISION may not be offered or will not be offered
in any member State other than France, except, pursuant to the
exemptions described in article 3(2) of the Prospectus Directive,
if they have been implemented by the relevant member State or in
any other circumstances not requiring GENOMIC VISION to publish a
prospectus as provided under article 3(2) of the Prospectus
Directive and/or regulations applicable in such member State.
This press release is for distribution only to persons who (i)
have professional experience in matters relating to investments
falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (as amended, the
"Financial Promotion Order"), (ii) are persons falling within
Article 49(2)(a) to (d) ("high net worth companies, unincorporated
associations etc") of the Financial Promotion Order, (iii) are
outside the United Kingdom, or (iv) are persons to whom an
invitation or inducement to engage in investment activity (within
the meaning of section 21 of the Financial Services and Markets Act
2000) in connection with the issue or sale of any securities may
otherwise lawfully be communicated or caused to be communicated
(all such persons together being referred to as "Relevant
Persons"). This press release is directed only at Relevant Persons
and must not be acted on or relied on by persons who are not
Relevant Persons. Any investment or investment activity to which
this press release relates is available only to Relevant Persons
and will be engaged in only with Relevant Persons.
The prospectus registered with the Autorité des Marchés
Financiers contains forward-looking statements. No guarantee is
given as to these forecasts being achieved, which are subject to
risks, including those described in the prospectus, and to the
development of economic conditions, the financial markets and the
markets in which GENOMIC VISION operates.
Genomic VisionAaron BensimonCo-founder, President &
CEOTel.: +33 1 49 08 07
50investors@genomicvision.comorNewCap.Investor Relations
& Financial CommunicationsDušan Orešanský / Emmanuel HuynhTel.:
+33 1 44 71 94 92gv@newcap.fr
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024